(IN BRIEF) Sandoz has launched Afqlir®, its biosimilar to aflibercept, across Europe following European Commission approval in 2024. Equivalent in efficacy, safety, and pharmacokinetics to Eylea®, Afqlir® provides a lower-cost treatment option for serious retinal diseases such as nAMD, RVO, … Read the full press release
Posted in Business, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged aflibercept, Afqlir, anti-VEGF market, biologic medicines, biosimilar portfolio, biosimilars, Christophe Delenta, DME, European Commission approval, European Rollout of Afqlir Marks Major Step in Sandoz Expansion Across Anti-VEGF Ophthalmology Market, Eylea, intravitreal injection, mCNV, nAMD, ophthalmology, retinal diseases, RVO, Sandoz, Sustainable Healthcare, vision loss treatment
Investment to help meet rising demand for licensed biologics and expected pipeline growth Basel, Switzerland, 16-10-2013 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced plans to invest 800 million Swiss francs within its global manufacturing network to increase production … Read the full press release
Posted in Business, Germany, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged Basel, biologic medicines, Daniel O’Day, Germany, Kadcyla, licensed biologics, Oceanside, Penzberg, Perjeta, pertuzumab, RoACTEMRA, Roche, Switzerland, tocilizumab, trastuzumab emtansine, USA, Vacaville
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?